Cat. No.: HY-13317

Oseltamivir

(Synonyms: GS 4104)

46 Cited Publications

Avis client

Based on 46 publication(s) in Google Scholar

Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC₅₀s of 0.67, 0.9, 1.34 and 13 nM, respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.94%
CAS No.: 196618-13-0
Formule: C₁₆H₂₈N₂O₄
Masse moléculaire:312.40

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Oseltamivir Chemical Structure

CAS No.: 196618-13-0

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vivo
Chemical Information
Publications (46)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	>200 μM Compound: OSV	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 31371135]
Fibroblast	CC₅₀	>10 μM Compound: OS carboxylate	Cytotoxicity against chicken embryo fibroblast after 2 days by MTS assay Cytotoxicity against chicken embryo fibroblast after 2 days by MTS assay	[PMID: 23664211]
Fibroblast	CC₅₀	>20 μM Compound: OS	Cytotoxicity against chicken embryo fibroblasts infected with Influenza A virus (A/Chicken/Shandong/LY/08(H9N2)) preincubated for 1 hr followed by viral-infection measured after 2 days by MTS assay Cytotoxicity against chicken embryo fibroblasts infected with Influenza A virus (A/Chicken/Shandong/LY/08(H9N2)) preincubated for 1 hr followed by viral-infection measured after 2 days by MTS assay	[PMID: 24262883]
HEK293	IC₅₀	>10000 μM Compound: oseltamivir carboxylate	Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	[PMID: 18694948]
HEK293	IC₅₀	>10000 μM Compound: oseltamivir carboxylate	Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	[PMID: 18694948]
HEK293	IC₅₀	>10000 μM Compound: oseltamivir carboxylate	Inhibition of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate Inhibition of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	[PMID: 18694948]
HEK293	IC₅₀	>6000 μM Compound: oseltamivir carboxylate	Inhibition of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate Inhibition of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	[PMID: 18694948]
HEK293	IC₅₀	0.05 μM Compound: OSV	Inhibition of Influenza A virus (A/California/04/2009 (H1N1) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay Inhibition of Influenza A virus (A/California/04/2009 (H1N1) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay	[PMID: 31324565]
HEK293	IC₅₀	0.1 μM Compound: OSV	Inhibition of Influenza A virus (A/Babol/36/2005 (H3N2) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay Inhibition of Influenza A virus (A/Babol/36/2005 (H3N2) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay	[PMID: 31324565]
HEK293	IC₅₀	2.6 μM Compound: OSV	Inhibition of Influenza A virus (A/Anhui/1/2005(H5N1)) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay Inhibition of Influenza A virus (A/Anhui/1/2005(H5N1)) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay	[PMID: 31324565]
HEK293	IC₅₀	441.3 μM Compound: OSV	Inhibition of Influenza A virus (A/Shanghai/1/2013 (H7N9)) neuraminidase R294K mutant expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay1 Inhibition of Influenza A virus (A/Shanghai/1/2013 (H7N9)) neuraminidase R294K mutant expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay1	[PMID: 31324565]
HEK293	IC₅₀	9.6 μM Compound: OSV	Inhibition of Influenza A virus (A/Anhui/1/2013 (H7N9) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay Inhibition of Influenza A virus (A/Anhui/1/2013 (H7N9) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay	[PMID: 31324565]
HEK-293T	IC₅₀	21.09 ng/mL Compound: Oseltamivir	Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	[PMID: 21123068]
HEK-293T	IC₅₀	5.13 μg/mL Compound: Oseltamivir	Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	[PMID: 21123068]
HEK-293T	CC₅₀	>250 μM Compound: OSV	Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 26924568]
LLC-PK1	IC₅₀	1.3 mM Compound: Oseltamivir	Inhibition of human MDR1-mediated digoxin permeability expressed in pig LLC-PK1 cells Inhibition of human MDR1-mediated digoxin permeability expressed in pig LLC-PK1 cells	[PMID: 19721074]
MDCK	CC₅₀	>3521 μM Compound: oseltamivir carboxylate	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 17194832]
MDCK	EC₅₀	0.0014 μM Compound: oseltamivir carboxylate	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	0.032 μM Compound: oseltamivir carboxylate	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	0.14 μM Compound: oseltamivir carboxylate	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	0.28 μM Compound: oseltamivir carboxylate	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	CC₅₀	>100 μM Compound: oseltamivir carboxylate	Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay	[PMID: 18778942]
MDCK	CC₅₀	>100 μM Compound: OSC	Cytotoxicity against MDCK cells by MTS assay Cytotoxicity against MDCK cells by MTS assay	[PMID: 19281225]
MDCK	EC₅₀	11.6 μM Compound: OSC	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	12 μM Compound: OSC	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	2.6 μM Compound: OSC	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	400 μM Compound: OSC	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	800 μM Compound: OSC	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	900 μM Compound: OSC	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	0.726 ng/mL Compound: oseltamivir carboxylate	Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication after 48 to 72 hrs by plaque assay Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication after 48 to 72 hrs by plaque assay	[PMID: 19364864]
MDCK	EC₅₀	10.23 ng/mL Compound: oseltamivir carboxylate	Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene after 48 to 72 hrs by plaque assay Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene after 48 to 72 hrs by plaque assay	[PMID: 19364864]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of compound after 1 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of compound after 1 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 1250 nM of compound after 6 passage after 48 hrs by hemagglutininin tit Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 1250 nM of compound after 6 passage after 48 hrs by hemagglutininin tit	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12 Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 3,125 nM of zanamivir after 6 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 3,125 nM of zanamivir after 6 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of zanamivir after 1 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of zanamivir after 1 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.3 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 16 uM of zanamivir after 7 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 16 uM of zanamivir after 7 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.4 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells selected at 3,125 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells selected at 3,125 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.4 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	0.4 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 6250 nM of compound after 7 passage after 48 hrs by hemagglutininin tit Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 6250 nM of compound after 7 passage after 48 hrs by hemagglutininin tit	[PMID: 19651908]
MDCK	IC₅₀	0.7 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	0.8 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.9 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 78 uM of zanamivir after 8 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 78 uM of zanamivir after 8 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	1.5 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo	[PMID: 19651908]
MDCK	IC₅₀	11.9 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	1178.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	1390 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 1950 uM of oseltamivir after 10 passage after 48 hrs by hem Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 1950 uM of oseltamivir after 10 passage after 48 hrs by hem	[PMID: 19651908]
MDCK	IC₅₀	145.2 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 6250 nM of oseltamivir after 7 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 6250 nM of oseltamivir after 7 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	1469.7 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	1502.8 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus	[PMID: 19651908]
MDCK	IC₅₀	152.8 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 781 uM of oseltamivir after 10 passage after 48 hrs Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 781 uM of oseltamivir after 10 passage after 48 hrs	[PMID: 19651908]
MDCK	IC₅₀	177 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 8 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 8 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	18.2 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M mutant infected in MDCK cells selected at 16 uM of oseltamivir after 7 passage after 48 hrs by hemagglutininin Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M mutant infected in MDCK cells selected at 16 uM of oseltamivir after 7 passage after 48 hrs by hemagglutininin	[PMID: 19651908]
MDCK	IC₅₀	180.3 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 9 passage after 48 hrs b Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 9 passage after 48 hrs b	[PMID: 19651908]
MDCK	IC₅₀	191.6 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 390 uM of oseltamivir after 9 passage after 48 hrs by hemag Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 390 uM of oseltamivir after 9 passage after 48 hrs by hemag	[PMID: 19651908]
MDCK	IC₅₀	2.1 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 31 uM of compound after 8 passage after 48 hrs by hemagglutininin titer Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 31 uM of compound after 8 passage after 48 hrs by hemagglutininin titer	[PMID: 19651908]
MDCK	IC₅₀	2.3 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G and E119G mutant infected in MDCK cells selected at 31 uM of zanamivir after 9 passage after 48 hrs by hemaggluti Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G and E119G mutant infected in MDCK cells selected at 31 uM of zanamivir after 9 passage after 48 hrs by hemaggluti	[PMID: 19651908]
MDCK	IC₅₀	25.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 1250 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 1250 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay	[PMID: 19651908]
MDCK	IC₅₀	27.8 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	3 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 781 uM of zanamivir after 10 passage after 48 hrs by hemagglutininin ti Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 781 uM of zanamivir after 10 passage after 48 hrs by hemagglutininin ti	[PMID: 19651908]
MDCK	IC₅₀	3.1 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	3009.1 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus	[PMID: 19651908]
MDCK	IC₅₀	4.5 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	498.9 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	5.3 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	5.7 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 1950 uM of zanamivir after 10 passage after 48 hrs by hemagglutinini Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 1950 uM of zanamivir after 10 passage after 48 hrs by hemagglutinini	[PMID: 19651908]
MDCK	IC₅₀	6.2 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 390 uM of zanamivir after 9 passage after 48 hrs by hemagglutininin Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 390 uM of zanamivir after 9 passage after 48 hrs by hemagglutininin	[PMID: 19651908]
MDCK	IC₅₀	6.4 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	6126 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	695.6 nM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	89.2 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 78 uM of oseltamivir after 8 passage after 48 hrs by hemagg Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 78 uM of oseltamivir after 8 passage after 48 hrs by hemagg	[PMID: 19651908]
MDCK	CC₅₀	>300 μM Compound: Oseltamivir	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 19729316]
MDCK	EC₅₀	6.25 μM Compound: Oseltamivir	Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	EC₅₀	8.3 μM Compound: Oseltamivir	Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	IC₅₀	194.1 nM Compound: B	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) in MDCK cells assessed as reduction in plaque number by plaque reduction assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) in MDCK cells assessed as reduction in plaque number by plaque reduction assay	[PMID: 20014777]
MDCK	IC₅₀	0.16 nM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.44 nM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	154 nM Compound: oseltamivir	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	245.5 nM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	33.25 nM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	430.59 nM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	5.49 nM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	8.06 nM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	9.18 nM Compound: oseltamivir	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD2 additional passages in MDCK cells by NA inhibition assay Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD2 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	CC₅₀	>100 μg/mL Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells by MTS assay Cytotoxicity against MDCK cells by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	0.1 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	0.2 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	1.5 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	2 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	3.8 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	4 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	2.24 μM Compound: oseltamivir	Cytotoxicity against MDCK cells after 48 hrs by neutral red dye assay Cytotoxicity against MDCK cells after 48 hrs by neutral red dye assay	[PMID: 20886838]
MDCK	CC₅₀	>100 μg/mL Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells assessed as cell viability by MTS assay Cytotoxicity against MDCK cells assessed as cell viability by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	>100 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	>100 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	12 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	28 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	6.9 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	9 μg/mL Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	12 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
MDCK	EC₅₀	23.5 μM Compound: Oseltamivir	Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
MDCK	EC₅₀	90 μM Compound: Oseltamivir	Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	4 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	45 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	5.6 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	77.6 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	9 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	9.7 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	IC₅₀	>2436.6 μM Compound: Tamiflu	Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 22824205]
MDCK	IC₅₀	2 μM Compound: Tamiflu	Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 22824205]
MDCK	CC₅₀	>100 μM Compound: OSV-C	Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	<0.01 μM Compound: OSV-C	Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	0.05 μM Compound: OSV-C	Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	0.05 μM Compound: OSV-C	Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	0.06 μM Compound: OSV-C	Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	0.82 μM Compound: OSV-C	Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	13.63 μM Compound: OSV-C	Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	CC₅₀	>35.17 μM Compound: Oseltamirvir-carboxylate	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 23811085]
MDCK	EC₅₀	0.11 μM Compound: Oseltamirvir-carboxylate	Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	[PMID: 23811085]
MDCK	EC₅₀	18.99 μM Compound: Oseltamirvir-carboxylate	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	[PMID: 23811085]
MDCK	EC₅₀	3.06 μM Compound: Oseltamirvir-carboxylate	Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	[PMID: 23811085]
MDCK	EC₅₀	3.52 μM Compound: Oseltamirvir-carboxylate	Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	[PMID: 23811085]
MDCK	EC₅₀	0.02 μM Compound: oseltamivir carboxylate	Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	0.09 μM Compound: oseltamivir carboxylate	Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	1.1 μM Compound: oseltamivir carboxylate	Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	1.9 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
MDCK	EC₅₀	5.4 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
MDCK	EC₅₀	6.5 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
MDCK	IC₅₀	0.004 μM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24313801]
MDCK	IC₅₀	0.03 μM Compound: oseltamivir	Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24313801]
MDCK	IC₅₀	0.001 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus A/California/07/2009 (H1N1) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days Antiviral activity against Influenza A virus A/California/07/2009 (H1N1) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days	[PMID: 24374271]
MDCK	IC₅₀	0.001 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus A/Hong Kong/8/1968 (H3N2) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days Antiviral activity against Influenza A virus A/Hong Kong/8/1968 (H3N2) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days	[PMID: 24374271]
MDCK	IC₅₀	>500 μg/mL Compound: Oseltamivir	Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	[PMID: 24583605]
MDCK	IC₅₀	1 μg/mL Compound: Oseltamivir	Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	[PMID: 24583605]
MDCK	IC₅₀	2.81 μg/mL Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	[PMID: 24583605]
MDCK	EC₅₀	0.11 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	1.5 μM Compound: oseltamivir carboxylate	Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	16 μM Compound: oseltamivir carboxylate	Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	21 μM Compound: oseltamivir carboxylate	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	29 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	3 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	>10 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus A/California/07/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/California/07/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus A/Georgia/20/2006 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/Georgia/20/2006 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus A/Mexico/4108/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/Mexico/4108/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus A/Puerto Rico/8/34 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/Puerto Rico/8/34 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	>10 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus A/Texas/48/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/Texas/48/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	EC₅₀	0.16 μM Compound: oseltamivir carboxylate	Antiviral activity against Influenza A virus A/New York/18/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay Antiviral activity against Influenza A virus A/New York/18/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay	[PMID: 25019388]
MDCK	CC₅₀	>80 μM Compound: Oseltamivir	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	EC₅₀	>80 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	EC₅₀	>80 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus H3N2 VR1679 infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay Antiviral activity against Influenza A virus H3N2 VR1679 infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	CC₅₀	>200 μM Compound: OSV	Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay	[PMID: 25681711]
MDCK	IC₅₀	15 μM Compound: OSV	Antiviral activity against influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as inhibition of plaque formation after 3 days at 37 degC Antiviral activity against influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as inhibition of plaque formation after 3 days at 37 degC	[PMID: 25681711]
MDCK	IC₅₀	46.5 μM Compound: OSV	Antiviral activity against influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by plaque assay Antiviral activity against influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by plaque assay	[PMID: 25681711]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells after 72 hrs by MTS assay Cytotoxicity against MDCK cells after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	15 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	2 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	2.3 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	2.9 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	20 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	4 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	>20 μM Compound: oseltamivir	Antiviral activity against oseltamivir/amantadine-resistant Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytocidal effect after 48 hrs by CellTiter-Glo assay Antiviral activity against oseltamivir/amantadine-resistant Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytocidal effect after 48 hrs by CellTiter-Glo assay	[PMID: 25815159]
MDCK	IC₅₀	2.7 μM Compound: oseltamivir	Antiviral activity against Influenza A virus (A/FM/1/47(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/FM/1/47(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 26110443]
MDCK	IC₅₀	1.07 μM Compound: oseltamivir	Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption	[PMID: 26132528]
MDCK	IC₅₀	0.015 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining	[PMID: 26316467]
MDCK	IC₅₀	0.025 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining	[PMID: 26316467]
MDCK	CC₅₀	321 μM Compound: OST	Cytotoxicity against MDCK cells after 72 hrs by XTT assay Cytotoxicity against MDCK cells after 72 hrs by XTT assay	[PMID: 26643220]
MDCK	EC₅₀	0.03 μM Compound: OST	Antiviral activity against Influenza A virus infected in MDCK cells after 72 hrs by yield reduction assay Antiviral activity against Influenza A virus infected in MDCK cells after 72 hrs by yield reduction assay	[PMID: 26643220]
MDCK	CC₅₀	>100 μM Compound: OSV	Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	>200 μM Compound: OSV	Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	>83.24 μM Compound: OSV	Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	0.82 μM Compound: OSV	Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	9.75 μM Compound: OSV	Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	IC₅₀	10 μM Compound: OSV	Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as protection against virus induced cytopathic effect after 40 hrs by Celltiter-Glo assay Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as protection against virus induced cytopathic effect after 40 hrs by Celltiter-Glo assay	[PMID: 26686929]
MDCK	IC₅₀	16.9 nM Compound: Tamiflu	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining-based microplate reader analysis Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining-based microplate reader analysis	[PMID: 26697718]
MDCK	IC₅₀	18.5 nM Compound: Tamiflu	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining-based microplate reader analysis Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining-based microplate reader analysis	[PMID: 26697718]
MDCK	CC₅₀	>250 μM Compound: OSV	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 26924568]
MDCK	EC₅₀	0.015 μM Compound: OSV	Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay	[PMID: 26924568]
MDCK	CC₅₀	300 μg/mL Compound: Oseltamivir	Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay	[PMID: 27720324]
MDCK	CC₅₀	>1000 nM Compound: 2; (OC)	Cytotoxicity against MDCK cells after 72 hrs by Alamar-Blue assay Cytotoxicity against MDCK cells after 72 hrs by Alamar-Blue assay	[PMID: 28385598]
MDCK	CC₅₀	>500 μM Compound: 1	Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay	[PMID: 29141777]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir	Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method	[PMID: 29541360]
MDCK	CC₅₀	160.3 μM Compound: Oseltamivir	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 30108810]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir	Cytotoxicity in MDCK cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer-Glo cell viability assay Cytotoxicity in MDCK cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer-Glo cell viability assay	[PMID: 30192544]
MDCK	CC₅₀	>200 μM Compound: OSV	Cytotoxicity against MDCK cells after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells after 40 hrs by CellTiter-Glo assay	[PMID: 30554131]
MDCK	CC₅₀	>100 μM Compound: Oseltamivir carboxylate	Cytotoxicity against MDCK cells assessed as change in cellular morphology Cytotoxicity against MDCK cells assessed as change in cellular morphology	[PMID: 32214762]
MDCK	EC₅₀	21.8 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	39.1 μM Compound: Oseltamivir carboxylate	Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	5.7 μM Compound: Oseltamivir carboxylate	Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	CC₅₀	>640 μM Compound: Oseltamivir	Cytotoxicity in MDCK cells assessed as reduction in cell viability Cytotoxicity in MDCK cells assessed as reduction in cell viability	[PMID: 32378892]
MDCK	EC₅₀	2.14 μM Compound: Oseltamivir	Antiviral activity against influenza A virus H3N2/95-359 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method Antiviral activity against influenza A virus H3N2/95-359 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method	[PMID: 32378892]
MDCK	IC₅₀	46.1 μM Compound: Oseltamivir	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay	[PMID: 32520560]
MDCK	CC₅₀	>200 μM Compound: Oseltamivir	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability Cytotoxicity against dog MDCK cells assessed as reduction in cell viability	[PMID: 34126455]
MDCK	CC₅₀	>800 μM Compound: OSC	Cytotoxicity against dog MDCK cells assessed as decrease in cell viability by CCK8 assay Cytotoxicity against dog MDCK cells assessed as decrease in cell viability by CCK8 assay	[PMID: 34411893]
MDCK	CC₅₀	7865.4 μM Compound: Oseltamivir	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34425312]
MDCK	CC₅₀	>300 μM Compound: OS	Cytotoxicity against dog MDCK cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 37413878]
MDCK	CC₅₀	>800 μM Compound: OS	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37517205]
MDCK	CC₅₀	>200 μM Compound: 2	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
MDCK	EC₅₀	583 nM Compound: Oseltamivir carboxylate, Tamiflu	Antiviral activity against Influenza B virus (B/Harbin/07/94) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by MTT assay Antiviral activity against Influenza B virus (B/Harbin/07/94) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by MTT assay	10.1039/C2MD20300F
MDCK	EC₅₀	98 nM Compound: Oseltamivir carboxylate, Tamiflu	Antiviral activity against Influenza A virus (A/Sydney/5/1997(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by MTT assay Antiviral activity against Influenza A virus (A/Sydney/5/1997(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by MTT assay	10.1039/C2MD20300F
MDCK	CC₅₀	>500 μM Compound: OSV	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay	10.1039/C6MD00292G
Vero C1008	CC₅₀	>100 μM Compound: Oseltamivir	Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition incubated for 48 hrs Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition incubated for 48 hrs	[PMID: 32771797]

In Vivo

Oseltamivir (20 mg/kg/day, p.o., twice daily for 10 days) prevented death in the H1N1pdm virus infection in mice^[2].
Oseltamivir (10 mg/kg/day, oral gavage, 5 days) together with Amantadine (HY-B0402) (15 or 30 mg/kg) has greater protection efficiency against H5N1 influenza virus infection in mice than monotherapy^[3].
Oseltamivir is also used together with Ribavirin (HY-B0434), or Favipiravir (HY-14768), or Peramivir (HY-17015A) to prevent influenza virus infection in mice^[4]^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 196618-13-0
Appearance Solid
Masse moléculaire 312.40
Formule C₁₆H₂₈N₂O₄
Color White to off-white
SMILES

O=C(OCC)C1=C[C@H]([C@@H]([C@H](C1)N)NC(C)=O)OC(CC)CC
Synonyms

GS 4104
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (46)

All In Vivo Efficacy StudyCell Imaging/StainingFlow CytometryHistological Imaging/StainingWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. [Abstract]

2021 Apr 24;6(1):165. PMID: 33895786
Nat Commun

Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in mice. [Abstract]

2026 Feb 19. PMID: 41714318
NPJ Digit Med

Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]

2025 Nov 21;8(1):712. PMID: 41272280
Sci Transl Med

Baloxavir alleviates severe disease and viremia in ferrets infected with avian- or bovine-origin influenza A(H5N1) virus. [Abstract]

2026 Feb 18;18(837):eadt3889. PMID: 41706870
Acta Pharm Sin B

A novel C-3-substituted oleanolic acid benzyl amide derivative exhibits therapeutic potential against influenza A by targeting PA-PB1 interactions and modulating host macrophage inflammation. [Abstract]

2025 Aug;15(8):4156-4173. PMID: 40893672

Oseltamivir purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Aug;15(8):4156-4173. [Abstract]

Six-week-old BALB/c mice were intranasally administered a 5-fold 50% lethal dose (LD₅₀) of A/WSN/1933 and were treated with A5 or Oseltamivir phosphate (OSP)(i.p.; 6 d) or PBS 12 h later. Graphs of body weight curves and Kaplan—Meier survival curves of infected mice for 14 days were shown.
Phytomedicine

Insights into the mechanism of action of pterostilbene against influenza A virus-induced acute lung injury. [Abstract]

2024 Jul:129:155534. PMID: 38583346
Chemosphere

Photocatalytic degradation of the antiviral drug Tamiflu by UV-A/TiO2: Kinetics and mechanisms. [Abstract]

2015 Jul:131:41-7. PMID: 25765262
Arch Pharm Res

The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity. [Abstract]

2018 Jun;41(6):664-676. PMID: 29572682
Biomed Pharmacother

Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs. [Abstract]

2018 Jan:97:385-394. PMID: 29091888
Bioeng Transl Med

IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. [Abstract]

2020 Dec 1;6(1):e10196. PMID: 33532594
Cell Prolif

Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. [Abstract]

2021 Jan;54(1):e12953. PMID: 33211371
Virulence

Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition on nucleic acid synthesis, mRNA splicing and protein stability. [Abstract]

2024 Dec;15(1):2301242. PMID: 38170681
J Ethnopharmacol

Interpretation of the anti-influenza active ingredients and potential mechanisms of Ge Gen Decoction based on spectrum-effect relationships and network analysis. [Abstract]

2024 Jan 30;319(Pt 2):117290. PMID: 37806538

Oseltamivir purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117290. [Abstract]

Oseltamivir phosphate (OP) (21.2 mg/kg; p.o.; once daily for 7 d). Lung indexes on day 4 post-infection with H1N1 (0.8 LD₅₀). Expression of H1N1-NP mRNA was measured using RT-PCR.
Food Funct

Neuraminidase inhibition of Dietary chlorogenic acids and derivatives - potential antivirals from dietary sources. [Abstract]

2016 Apr 20;7(4):2052-9. PMID: 27010419
Commun Biol

Oseltamivir and baloxavir monotherapy and combination therapy efficacy against clade 2.3.4.4b A(H5N1) influenza virus infection in ferrets. [Abstract]

2026 Jan 26;9(1):324. PMID: 41588212
Inflammation

Siglec-E Ligand Downregulation on Hippocampus Neurons Induced Inflammation in Sevoflurane-Associated Perioperative Neurocognitive Disorders in Aged Mice. [Abstract]

2024 Feb;47(1):30-44. PMID: 37603227

Oseltamivir purchased from MedChemExpress. Usage Cited in: Inflammation. 2024 Feb;47(1):30-44. [Abstract]

Oseltamivir (OS) (30 or 100 μg/mL), a neuraminidase inhibitor, was used to block the increased neuraminidase effect induced by sevoflurane. 100 μg/mL Oseltamivir (OS) recovered the Siglec-E ligand level decrease in cultured primary hippocampal neurons.
Int J Mol Sci

Lycorine Inhibits Influenza Virus Replication by Affecting Nascent Nucleoporin Nup93 Synthesis. [Abstract]

2025 Jun 3;26(11):5358. PMID: 40508167
Int J Mol Sci

Antiviral Effects of ABMA and DABMA against Influenza Virus In Vitro and In Vivo via Regulating the Endolysosomal Pathway and Autophagy. [Abstract]

2022 Apr 1;23(7):3940. PMID: 35409297
Int J Mol Sci

Antiviral Activity of Benzoic Acid Derivative NC-5 Against Influenza A Virus and Its Neuraminidase Inhibition. [Abstract]

2019 Dec 12;20(24):6261. PMID: 31842256

Oseltamivir purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2019 Dec 12;20(24):6261. [Abstract]

The ICR mice were infected with influenza A virus (8 × LD₅₀) and received Oseltamivir phosphate (OS) (100 mg/kg; twice daily for 5 days).
Pharmaceuticals (Basel)

Herbacetin Alleviates Influenza Virus-Induced Lung Injury and Fibrosis by Targeting the Neuraminidase Protein. [Abstract]

2025 Aug 30;18(9):1306. PMID: 41011177

Oseltamivir purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Aug 30;18(9):1306. [Abstract]

Oseltamivir (OSE) (15 mg/kg/day; i.p.) did not cause significant weight loss or mortality after viral infection in the mice. Lung index data showed that Oseltamivir (OSE) treatment significantly reduced lung inflammation.

Oseltamivir purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Aug 30;18(9):1306. [Abstract]

Oseltamivir (OSE) (15 mg/kg/day; i.p.) treatment markedly reduced collagen deposition. Statistical data on inflammatory infiltration, pulmonary edema, and fibrotic area were provided. These results indicated that Oseltamivir (OSE) reduced lung injury and PF induced by IAV in vivo.

Oseltamivir purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2025 Aug 30;18(9):1306. [Abstract]

Results from immunohistochemical analysis for TGF-β1, collagen I, and Fn in the lung tissues from each group of mice were provided, accompanied by relevant statistical data. The Oseltamivir (OSE) (15 mg/kg/day; i.p.) group demonstrated reductions in these proteins within lung tissue.
J Med Virol

Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses. [Abstract]

2023 Jul;95(7):e28968. PMID: 37489704
Int J Infect Dis

Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. [Abstract]

2024 Jun 27:107134. PMID: 38944411
Front Cell Dev Biol

Neuraminidase1 Inhibitor Protects Against Doxorubicin-Induced Cardiotoxicity via Suppressing Drp1-Dependent Mitophagy. [Abstract]

2021 Dec 17:9:802502. PMID: 34977042
BMC Microbiol

Taurultam shows antiviral activity against SARS-CoV-2 and influenza virus. [Abstract]

2025 May 15;25(1):292. PMID: 40375181
Lab Invest

Hepatitis B virus core protein promotes the expression of neuraminidase 1 to facilitate hepatocarcinogenesis. [Abstract]

2020 Dec;100(12):1602-1617. PMID: 32686743

Oseltamivir purchased from MedChemExpress. Usage Cited in: Lab Invest. 2020 Dec;100(12):1602-1617. [Abstract]

After the HBc-positive cells are treated with OP (Oseltamivir phosphate), the phosphorylation of ERK and P65 significantly declined, the expression of IkBα increased, and the expression of nuclear P65 decreased.
Virol Sin

Enhancing the stability of influenza a reporter viruses by recoding the gfp gene. [Abstract]

2026 Jan 29:S1995-820X(26)00011-8. PMID: 41619854

Oseltamivir purchased from MedChemExpress. Usage Cited in: Virol Sin. 2026 Jan 29:S1995-820X(26)00011-8. [Abstract]

MDCK-PB2 cells were infected with H5N1/ΔPB2(300)-rGFP and then maintained in medium containing Oseltamivir (0.01–100 μM; 48 h; 37℃). The fluorescence microscopy images of the infected cells were recorded.

Oseltamivir purchased from MedChemExpress. Usage Cited in: Virol Sin. 2026 Jan 29:S1995-820X(26)00011-8. [Abstract]

Detection of NP expression in H1N1/ΔPB2(300)-rGFP infected and Oseltamivir (0.01–100 μM; 48 h; 37°C) treated MDCKPB2 cells.
Antiviral Res

Influenza A(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models. [Abstract]

2025 May 3:106174. PMID: 40324597
Virol Sin

Antiviral activity of vitamin D derivatives against severe fever with thrombocytopenia syndrome virus in vitro and in vivo. [Abstract]

2024 Aug 19:S1995-820X(24)00134-2. PMID: 39168248
Antiviral Res

Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy. [Abstract]

2020 Apr;176:104751. PMID: 32088248
Antiviral Res

Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase. [Abstract]

2016 Mar:127:68-78. PMID: 26802558
Sci Rep

Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice. [Abstract]

2021 Aug 11;11(1):16293. PMID: 34381119
Virol J

Bisbenzylisoquinoline alkaloids inhibit influenza virus replication by disrupting endosomal acidification. [Abstract]

2025 Jun 4;22(1):181. PMID: 40468427
ACS Infect Dis

Development of a Universal Type A Influenza Viral RdRp-Induced Reporter System with Potential for Antiviral Drug Screening. [Abstract]

2025 Jun 13;11(6):1437-1447. PMID: 40421776
Viruses

A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase. [Abstract]

2018 Jun 13;10(6). pii: E325. PMID: 29899269
Animal Model Exp Med

Antiviral effects and mechanism of Qi pi pill against influenza viruses. [Abstract]

2025 Jan 26. PMID: 39865580
Phytochemistry

Pogocablenes A-O, fifteen undescribed sesquiterpenoids with structural diversity from Pogostemon cablin. [Abstract]

2023 Oct:214:113829. PMID: 37597718
Chem Biodivers

Highly Conjugated Ergosterols With Anti-Influenza Virus Activity From the Marine-Derived Fungus Eutypella Sp. F0219. [Abstract]

2024 Nov 24:e202402465. PMID: 39581859
Virology

The combinatorial activities of oseltamivir and molnupiravir against influenza virus infections in vitro and in vivo. [Abstract]

2025 Oct:611:110642. PMID: 40730007
Virology

Recombinant A(H6N1)-H274Y avian influenza virus with dual drug resistance does not require permissive mutations to retain the replicative fitness in vitro and in ovo. [Abstract]

2024 Feb:590:109954. PMID: 38086284
Virology

Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. [Abstract]

2020 Jun;545:1-9. PMID: 32174453
Biosci Biotechnol Biochem

Orientin suppresses oxidized low-density lipoproteins induced inflammation and oxidative stress of macrophages in atherosclerosis. [Abstract]

2020 Apr;84(4):774-779. PMID: 31829093
bioRxiv

2025 Jul 31.
bioRxiv

Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection. [Abstract]

2024 Jul 7:2024.07.04.601620. PMID: 39372755
bioRxiv

Oseltamivir (Tamiflu), a Commonly Prescribed Antiviral Drug, Mitigates Hearing Loss in Mice. [Abstract]

2024 May 8:2024.05.06.592815. PMID: 38765999
bioRxiv

2023 Aug 12.
Universidade de São Paulo

2020 Sep.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (320.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2010 mL

16.0051 mL

32.0102 mL

5 mM

0.6402 mL

3.2010 mL

6.4020 mL

10 mM

0.3201 mL

1.6005 mL

3.2010 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. O Ferraris, et al. Sensitivity of Influenza Viruses to Zanamivir and Oseltamivir: A Study Performed on Viruses Circulating in France Prior to the Introduction of Neuraminidase Inhibitors in Clinical Practice. Antiviral Res. 2005 Oct;68(1):43-8. [Content Brief]

[2]. Smee DF, et al. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016 Dec;136:45-50. [Content Brief]

[3]. Ilyushina NA, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12(3):363-70. [Content Brief]

[4]. Ilyushina NA, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008 Nov;52(11):3889-97. [Content Brief]

[5]. Smee DF, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010 Oct;88(1):38-44. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2010 mL	16.0051 mL	32.0102 mL	80.0256 mL
	5 mM	0.6402 mL	3.2010 mL	6.4020 mL	16.0051 mL
	10 mM	0.3201 mL	1.6005 mL	3.2010 mL	8.0026 mL
	15 mM	0.2134 mL	1.0670 mL	2.1340 mL	5.3350 mL
	20 mM	0.1601 mL	0.8003 mL	1.6005 mL	4.0013 mL
	25 mM	0.1280 mL	0.6402 mL	1.2804 mL	3.2010 mL
	30 mM	0.1067 mL	0.5335 mL	1.0670 mL	2.6675 mL
	40 mM	0.0800 mL	0.4001 mL	0.8003 mL	2.0006 mL
	50 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6005 mL
	60 mM	0.0534 mL	0.2668 mL	0.5335 mL	1.3338 mL
	80 mM	0.0400 mL	0.2001 mL	0.4001 mL	1.0003 mL
	100 mM	0.0320 mL	0.1601 mL	0.3201 mL	0.8003 mL

Keywords

Oseltamivir

46 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Oseltamivir

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Oseltamivir

Activité biologique

Chemical Information

Publications (46)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Oseltamivir

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Oseltamivir

Activité biologique

Chemical Information

Publications (46)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Oseltamivir Related Classifications

Cat. No.: HY-13317